The goal ofthis study was to determine whether postoperative (implantation ofa stapes prosthesis) hearin g gain and the amount of air-bone gap overclosure are more improved with the Tefl on-wire piston or with the stainless-steel bucket prosthesis. We retrospectively reviewed the outcomes of82 surge ries that had been performed by the primal)' autho r; 41 of these patients had received a Fisch Tefl on-wire piston, and 41 had received a Baileymodified Robins on stainless-steel bucket prosthesis.
Introduction
Over the past 40 yea rs, there has been a sig nifica nt evo lution in stapes surge ry, from total footplate removal with a polyeth ylene strut to wire-tiss ue prosthesis and, more recen tly, to parti al stapedecto my and small-fenestra stape dotomy with various Teflon and stainless-steel pistons.':' Th e prop on ent s of eac h techn ique have advocated that their respec tive procedures and prostheses provide better hearin g result s.
. Th e evolution from total footpl ate rem oval to smallfenestra stapedec tomy and stapedotomy has reduced the risk of labyrinth traum a and imp roved hear ing, part icu- ' v" It is recognized that the sm all-fenestra stape doto my is techni call y more difficult to perform than the total or partial foo tplate removal techn iques," Part ial foo tplate removal wit h a Robinson bucket prosthesis is thought to be simpler and to provide more overc1osure of the preoperative air-b one gap.' ?Mos t authors who have compared hearin g with one prosth esis with that of another also use different surgi cal techniques, which could have an effect on their result s. Perkins and Curto demonstrated that the use of a bucket pro sthesis with a tissue seal result ed in significa ntly better hearing than either a bucket or a Teflon-wir e piston with a blood seal (the latter two techn iques were com parable to eac h other) ." Elonka et al repor ted improved hearing with a Robin son stai nless -stee l prosthe sis, but that imp rovement was not sig nifica ntly better than that obtai ned with a House wire prosth esis." Is one prosth esis superior to anoth er? Our study indicates that there is no statistically significa nt diffe renc e in hearing ga in or air -bo ne gap overc1osure between the Teflon-wire and stainless -steel buc ket prosth eses.
Materials and Methods
From a personal series of 829 stapes operations by the primary author, we retrospecti vely reviewed the records of 4 1 patients, age d 8 to 75 (mean: 49), who und erwent a small-fe nestra stape doto my with a Fi sch Teflon-wire piston over a tissue sea l. We compared their out comes with those of 41 pati ents, aged 24 to 76 (mea n: 50), who und erw ent a partial stapedectomy with a stainless-steel Bailey-modified Robinson prosthesis and a tissue seal. We co mpared the amount of hearing ga in and overclos ure of the air-bo ne gaps to determine whether or not one prosth esis or technique yie lded superior res ults.
Six of the 4 1 Teflon -wire surgeries and 4 of the 41 stain less -steel pro cedures were revis ion operations; the rema inder were prim ary opera tions. Pre-and postoperative (6 mo) audiolog ic testin g data (air co nduction studies at 0.5, 1, 2, and 4 kHz) were analyzed. The amo unt of hearing gain was calculated by comparing pre-and postopera tive air conduction, while the amount of air-bone gap overclosure was calculated by comparing postoperative air conduction with preoperative bone conduction.
Surgical Techniques
A Fisch Teflon-wire prosthesis (Xorned-Treace ; Jacksonville, Fla.), 0.4 mm in diameter, was cut to length. The average over-incus length was 5.25 mm. The Teflon shaft of the piston was cut to extend into the vestibule 0.25 mm below the level of the footp late.
The stai nless-steel bucket prosthesis was a Baileymodified Robinson prosthesis (Xo med-Treace) with a O.4-mm diameter shaft. The overall length of the stainless-steel prosthesis was 4.25 mm, and the under-incus length was 4 mm. We selec ted either the standard 0.87mm pros thesis or the large-well l.O-mm prosthesis, depending on the size of the lenticular process of the incus.
Local anesthesia with sedation was administered to all patient s before the surgical field was prepared. The postauricular area was injected with 2% lidocaine and epinephrine in a I:100,000 solution. Then a 1:50,000 solution was injected into the ear cana l and, after the field was draped , 0.5 ml of a I:3,000 lidocaine and epinephrine solution was injec ted to infiltrate the deep external ear canal. Pre-and intraoperative sedation was administered to augme nt the local anesthesia.
In all patients, an areolar fasc ia harvested from the pos tauricular muscle was used to seal the oval window or small fenestra. Patients who underwent the small-fenestra technique received a dry-press fascia, while those who underwent the stainless-steel bucket technique received a loose, wet fascia .
A speculum holder was employed during surgery, which allowe d the surgeon to use both hands. A transmeatal approac h was employed to expose the oval window , thereby preserving the chordae tympani nerve . An argon laser with a fiberop tic otologic probe was used on all patients. The duration of the single-pulse settings was 0. 1 second. Power was set at a minimal wattage , sufficient to create an adequate burn on the stapes footplate.
Teflon -Wire Piston
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in theseteratogeni citystudies, there werealso reductions in maternalbody weightgai n andeffects on fetal growth (lower fet albody weightsand/or del ayed ossification) in mi ce (60and 180mcglkg), rabbits (150mcglkg),andrats(600mcglkg).
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Carcinogenesis, Mutagenesis, Impairment of Fertility: in SpragueDawley rats, momet asonefuroate demonstratednostat istically significant increase in theincidence of tumors at an inhal ation dose of 67 mcg/kg(approximateiy 3 times the maximum recomm endeddaily intranasal dose in adults on a mcg/m' basis). In Swiss CD·l mice, mometasone furoate demonstratedno statistical ly significant increaseintheincidenceoftumors atan inhalationdoseof 160mcglkg(approxima tely4 times themaximum recommended daiiyintranasaldoseinadultsonamcg/m' basis).
Atcytotoxic doses, mometasonefuroat e produced an increase in chromosome aberrationsin vitro in Chinesehamsterovary-cellculturesinthenonacti vat ionphase, butnotinthepresenceof ratliverS9 fraction. Mometasone furoate was not mutagenic in the mouse-lymphoma assay and the Salmonel/aiE. col Umammalianmicrosomemut at ionassay, aChi nese hamster lung cell (CHL) chromosomal-aberrations assay, an in vivomousebone-marroweryt hrocyte-micronucleusassay, a ratbone-marrow clast ogenicity se rved. An argo n laser with a fiberoptic oto logic pro be was used to create multipl e bum s in the cen tral portion of the stapes footplate . Th e ch ar and marg in of the rosette were debrided with a 0.5 -and 0.6-mm ova l window rasp, creating a fenes tra 0.7 mm in diameter. A small piece of pres sed areo lar fasc ia, measuri ng 1.5 by 1.5 mm, was place d over the fenestra, sealing the vestibule. Th e 0.4mm Teflon-wire piston was cut to length . It was then inserted and depressed into the vestibule 0.25 mm through the fenes tra . Th e stainless-stee l wire was then cr impe d onto the distal end of the incu s. After the prosthesis was sec ure d, the incudostapedia l j oint was separated. Th e stapedius tendon and the posterior crura of the stapes were cut with the argon laser beam . Th e anterior crura was fractured inferiorl y toward the prom ont ory. After the sta pes supers truc ture was moved , the position and mobility of the prosth esis was confirmed by gentle palp ation. The eardrum was returned to its norm al position. Measurement s were made of the preoperative dur ation of bone co nduction and the postopera tive duration of air conduc tion. Hear ing was tested intrao perative ly with a 512 tuning fork . Foll owing the procedu re, the ea r ca nal wa s packed with antibiotic-saturated ga uze for 5 to 7 days."
Bailey-Modified Robinson Bucket Prosthesis
Aga in, the transmeatal approach ex posed the oval window and stapes and preserv ed the chordae tymp ani ner ve. The incu dos tapedia l j oint was di vided . Th e stapedius tend on was avulsed from the stapes arch with a 90°stapes pick and preser ved for later reco nstructio n.S'" The argon laser and fiberoptic probe were used to di vide the posteriorcrura . The anterior crura was first fractured superior ly toward the facial ner ve and then inferiorly toward the promontory to reduc e the risk of a green stick fracture or stapes mobili zation. A rose tte was created with the argo n laser in the central porti on of the stapes footplate and exten ded to the superior and inferio r margins of the stapes foo tplate. Oval window ras ps of 0.5 and 0.6 mm were used to debride the char fro m the rose tte and to eleva te the pos terior one-third to one -ha lf of the stapes footpl ate out of the oval window niche. The mucosa of the ova l window was scarified with the oval window rasp . A moist areolar fasc ia mea suring 2 by 2 mm was place d in the ova l window , sealing the ves tibule. T he bucket prosth esis was placed in the ova l window and initia lly suppor ted by the wet fasc ia. Th e well of the prosth esis was positioned under the lent icular process by gently eleva ting the incus while depressing the prosth esis slightly. After the bucket was pos itio ned, the wire bale was rotated over the incu s. Gentl e palp ation of the incus was used to con firm the positi on and mob ility of the prosthesis.P Th e stapedius tend on was reattached to the buck et of the pro sth esis. Aft er retu rning the eardrum, intraoperati ve tuning fork Volume 78, Number 4
Treatment for Negative Pressure and Ot it is
Th e Otovent m eth od is design ed to tr eat many of th e com plicati ons associated with negative ear pr essur e caused by Eustach ian tub e dy sfun ction.
Otovent can prevent or tr eat Otit is medi a and can be an alternative to surgery.
Proven success in clini cal study. Th e difference in hearing gain between the T eflon and sta inless-steel group s was not statistica lly significant afte r either primary surgery (p = 0.291) or revis ion surgery (p = 0.983).
In patients who und erw ent primary surgery , the re was no statistically significant difference between the Tef lon and stainless-steel group s in the number of patient s wh o ac hieved ove rclos ure of the ai r-bo ne gap (p = 0.083) or in the amo unt of ove rclos ure (p = 0.730) . Teflon-wire prosthesis than with the stainless-steel bucket prosthesis-23.3 and 20.3 dB, respectively, in primary cases, and 20.5 and 20.3 dB, respectively in revision surger ies; however, these differe nces were not statistically significa nt.
No. Mean Patients Gain
Among the patients in the Teflon -wire primary group who achieved overclosure, the amount of improvement was 4.4 dB, which was not significantly different from the 5.2 dB improvement seen in the stainless-steel bucket primary patients who achieved overclosure. Like wise, the difference between the number of patients who achie ved overclosure in the two grou ps was not significant statistically (6/35 vs. 13/37, respective ly; p = 0.083 ), although the trend favore d the stainless-steel bucket gro up. ' We conclude that an experienced stapes surgeon will not find any significant difference in hearing gain or in the amount of overclosure of the preoperative air-bone gap between a Teflon-wire procedure and stainless-steel bucket procedure , even thou gh there may be a tendency toward better overclosure with the latter. This observation has previou sly been noted by others, notably House (" I have always believed that it is not the particular technique, but the hands and judgment applying the tech nique that is
Discussion
The result s of most compari sons between the two prosth eses are often skewed by differences in surgical techniques.v?"!' According to the liter ature, it appears that a small-fenestra stapedotomy and partial footplat e removal stapedectomy results in superior hearing and confers a lower risk of trauma to the labyrinth than does a total footpl ate removal stapedectomy. In this study, we compared hearing impro vement among patients who receive d two different types of prostheses that were implanted under the slightly different surgical techniqu es that are necessary to accommodate the design of eac h. Although the sequence of the surgical steps was different , the management of the stapes footplate was similar. In both the Teflon-wire piston and the stainless-steel bucket procedures, laser energy was used to create a smallfenestra stapedotomy. The placement of the bucket prosthesis was facilit ated by removing the posterior footplate rather than by making a small fenestra in the central footplate. In both procedures, a fascia was used to seal the oval window or small fenestra, thereby creating an annular membr ane around the prosth esis. " The shaft of both prostheses was 0.4 mm in diameter.
The hearing gain appe ared to be slightly higher with the
Results
Among the 72 patients who underwe nt primary stapes surgery, 35 recei ved a Teflon-wire prosthesis and 37 received a stainless-s teel bucket prosthe sis (table I) . The postoperative hearing gain was 23.3 dB in the Teflon-wire patients and 20.7 dB in the stainless-s teel bucket patients-not a statistically significant difference (p =0.291).
Among the 10 patients who unde rwent revision surgery, the mean hearin g gain was 20.5 dB in the 6 patients in the Teflon-wire group and 20.3 dB in the 4 patients in the stainless-steel bucket group-again, not a statistically significant difference (p = 0.983).
Overclosure of the preop erative air-bone gap was achieved in 6 of the 35 patients who underwent the primary Teflon-wire procedure (mea n overclosure: 4.4 dB) and in 13 of the 37 patients who underwent the primary stainless-steel bucket procedu re (mean: 5.2 dB) (table 2). The differ ence between the number ofpatients who achieved overclo sure with the two techniques approached, but did not reach, statistical significance in favor of the stainless-steel bucket prosthesis (p = 0.083). The mean amount of overclos ure was slightly higher in the stainless-steel bucket group, but the differen ce was not statistically significant (p = 0.730 ).
None of the 10 patients who underwent revision surgery achieved overclosure.
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The Hearing Enhancer for patients who aren't ready for a hearing aid.
Mill ions of people occasiona lly need hearing assistance due to a mild hearing impairment, but th ey aren' t ready for a hearin g "aid': That's why ReSound created th e revolutionary new Avanc e Hearin g Enhan cer.
Simple, inexpe nsive, and virtually invisible when worn, Avanc e can be slipped onto the ear whe n a patient needs co nfidence in their abi lity to hear-during important meetings, for example, or in restauran ts or auditoriums.
Avan ce is easy for you, too: pat ients can be tested and fit in one 30-min ute office visit. And beca use Ava nce is a "h ear ing enha n cer" rather th an a hearing "aid': it allows your pract ice to serve many new patien ts who might not othe rwise have visited you.
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For more information Circle 111 on Reader Service Card FARRIOR, TE MPLE vital to success") " and Shee hy ("If a techn ique is working for you, do n't change for change's sake") .'?
The selec tion of a given stapes prosthesis is simply a matter of cho ice, based more on certain tec hnica l aspect s of the prosthesis place me nt and attac hme nt to the incus than on the potent ial for sig nificant hearing ga in or airbone ga p overclosure . An ex pe rie nced stapes surgeon who is ge tting goo d result s with a particu lar prosthesis has no reaso n to fee l that chang ing to another prosth esis will significa ntly alter these result s.
